Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

Pipeline

CPC-200

 

CPC-200, Colby's co-lead small molecule is a molecularly-targeted oxidase enzyme inhibitor drug which is being developed for a Phase l/lla clinical trial in 2010 as a therapeutic drug for the treatment of high risk solid cancer patients with tumors recurring after surgical or radiation de-bulking of the primary tumor.

CPC-200 is a synthetic drug that irrversably binds to and inactivates the oxidase enzyme producing hydrogen peroxide in the cell cytoplasm of several types of solid tumors with unmet medical needs. Therapeutic treatment with CPC-200 in experimental mouse models of solid cancers show a significant overall survival benefit and decreased time to tumor progression.